Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01226732 · ClinicalTrials.gov registry record · Phase 1
A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors
A Phase 1 study of Metastatic or Unresectable Solid Tumor Malignancy, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 3
- Study locations
NCT01226732: Completed Phase 1 study of Metastatic or Unresectable Solid Tumor Malignancy, sponsored by SCRI Development Innovations.
NCT01226732 is a Phase 1 study of Metastatic or Unresectable Solid Tumor Malignancy that has completed, run by SCRI Development Innovations. The registered enrollment target is 23 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01226732, a Phase 1 study of Metastatic or Unresectable Solid Tumor Malignancy, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 3
- Study locations
Study Summary
The investigators propose this Phase I trial of the combination of AUY922 and capecitabine to determine the maximum tolerated dose (MTD) in patients with advanced solid tumors. This combination treatment has potential applicability in tumor types where capecitabine or fluorouracil is a treatment option, including colorectal and breast cancer.
Primary Outcome
To determine the maximum tolerated dose (MTD) of AUY922 plus capecitabine in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Hsp90 Inhibitor AUY 922
Study Locations (3)
Florida
- Florida Cancer Specialists - Fort Myers
Oklahoma
- Oklahoma University - Oklahoma City
Tennessee
- Tennessee Oncology - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2010-11 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
What the finished NCT01226732 record still lists
NCT01226732 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Metastatic or Unresectable Solid Tumor Malignancy appearing as the primary indexed condition, and to 2 interventions - of which Capecitabine is the first listed.
NCT01226732 reports a single indexed study location in Florida, Oklahoma, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01226732 about?
NCT01226732 is a clinical study titled "A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors". The investigators propose this Phase I trial of the combination of AUY922 and capecitabine to determine the maximum tolerated dose (MTD) in patients with advanced solid tumors. This combination treatment has potential applicability in tumor types where capecitabine or fluorouracil is a treatment opt...
What is the current status of trial NCT01226732?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2010-11. Estimated completion is 2014-06.
What conditions does trial NCT01226732 study?
This clinical trial studies the following conditions: Metastatic or Unresectable Solid Tumor Malignancy.
What interventions are being tested in trial NCT01226732?
The interventions under investigation include: Capecitabine (DRUG), Hsp90 Inhibitor AUY 922 (DRUG).
Who is sponsoring clinical trial NCT01226732?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01226732 being conducted?
This trial has 3 study locations across Florida, Oklahoma, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01226732's enrollment target sits among peer trials
23 1596th of 2000 higher than 400 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia